Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.

PubWeight™: 2.16‹?› | Rank: Top 2%

🔗 View Article (PMID 7748217)

Published in Arthritis Rheum on May 01, 1995

Authors

M Dougados1, S vam der Linden, M Leirisalo-Repo, B Huitfeldt, R Juhlin, E Veys, H Zeidler, T K Kvien, I Olivieri, B Dijkmans

Author Affiliations

1: Université René Descartes, Hôpital Cochin, Paris, France.

Articles citing this

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00

Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71

Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum (2010) 2.52

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86

Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70

Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis (2004) 1.58

Conventional treatments for ankylosing spondylitis. Ann Rheum Dis (2002) 1.48

Third International Workshop on Reactive Arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis (1996) 1.47

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46

Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center. Rheumatol Int (2011) 1.40

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther (2006) 1.37

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis (2005) 1.17

Developments in therapies for spondyloarthritis. Nat Rev Rheumatol (2012) 1.17

Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis (2002) 1.09

Ankylosing spondylitis. Not just another pain in the back. Can Fam Physician (2004) 1.01

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs (2014) 1.00

A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98

Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed (2007) 0.94

Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93

Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol (2010) 0.92

Rheumatic manifestations of psoriasis. Clin Rheumatol (2006) 0.92

Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clin Rheumatol (1998) 0.90

Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis (2002) 0.90

Stimulation of whole blood cultures in patients with ankylosing spondylitis by a mitogen derived from Mycoplasma arthritidis (MAS) and other mitogens. Rheumatol Int (1997) 0.88

New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. Ann Rheum Dis (2001) 0.86

Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. Ann Rheum Dis (2002) 0.86

Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis (1997) 0.85

Expanding the armamentarium for the spondyloarthropathies. Arthritis Res Ther (2004) 0.83

Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study. Clin Rheumatol (2013) 0.83

Juvenile ankylosing spondylitis--is it the same disease as adult ankylosing spondylitis? Rheumatol Int (2003) 0.82

Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East. Clin Rheumatol (2012) 0.82

Conventional therapy for Crohn's disease. World J Gastroenterol (2006) 0.82

Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. BMC Gastroenterol (2001) 0.80

Juvenile spondyloarthritis treatment recommendations. Am J Med Sci (2012) 0.79

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis (2001) 0.78

The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int (2006) 0.78

Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. Rheumatol Int (2013) 0.78

The microbiome, HLA, and the pathogenesis of uveitis. Jpn J Ophthalmol (2015) 0.77

[Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study]. Z Rheumatol (2006) 0.75

Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatol Int (2009) 0.75

Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2003) 0.75

Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis. Clin Med Insights Arthritis Musculoskelet Disord (2017) 0.75

Heel pain due to psoriatic arthritis in a 50 year old recreational male athlete: case report. J Can Chiropr Assoc (2011) 0.75

Efficacy of an acquainted drug in the treatment of inflammatory low back pain: sulfasalazine under investigation. Drug Des Devel Ther (2016) 0.75

Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. Eur J Rheumatol (2017) 0.75

Management of childhood arthritis. Part 2: Chronic arthritis. Arch Dis Child (1997) 0.75

Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. Medicine (Baltimore) (2015) 0.75

Periodontal Pathogens are Likely to be Responsible for the Development of Ankylosing Spondylitis. Curr Rheumatol Rev (2015) 0.75

Treatment of ankylosing spondylitis: focus on etanercept. Biologics (2007) 0.75

[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis]. Wien Med Wochenschr (2008) 0.75

Extraintestinal Complications of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2001) 0.75

[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy]. Z Rheumatol (2011) 0.75

Clinical observations programme in SpA: disease parameters, treatment options and practical management issues. Rheumatol Int (2008) 0.75

[Infection-induced reactive arthritis : etiopathogenesis, clinical spectrum, therapy]. Z Rheumatol (2013) 0.75

Articles by these authors

Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82

The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 5.00

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78

ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31

EULAR recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 3.37

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis (2008) 3.02

Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95

Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol (1999) 2.93

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72

Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum (2000) 2.71

[Rheumatology: Integration into student training--the RISA- Study. Results of a survey exploring the scale of education and training in rheumatology at German universities]. Z Rheumatol (2004) 2.69

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37

[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol (1997) 2.34

Coexistence of ochronosis and ankylosing spondylitis. J Rheumatol (1990) 2.30

New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20

Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis (2002) 2.20

Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum (2001) 2.20

Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol (2000) 2.12

Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum (1991) 2.10

Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis (1998) 2.09

Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07

Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology (1989) 2.06

Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol (2012) 2.03

Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum (2011) 2.01

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97

Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis (1999) 1.97

Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol (1988) 1.96

Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol (1998) 1.93

[Health economics research in the area of chronic polyarthritis]. Z Rheumatol (2002) 1.91

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis (2007) 1.87

Smoking in Crohn's disease: effect on localisation and clinical course. Gut (1992) 1.87

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86

Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis (1992) 1.86

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82

Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum (1998) 1.81

Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis (2007) 1.78

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78

Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum (2000) 1.77

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76

The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis (2001) 1.70

Psoriatic arthritis. Curr Opin Rheumatol (1998) 1.69

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66

Genetic markers and quantitative genetic variation in Medicago truncatula (Leguminosae): a comparative analysis of population structure. Genetics (1996) 1.65

Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum (2001) 1.65

Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis (2008) 1.65

Histopathology of intestinal inflammation related to reactive arthritis. Gut (1987) 1.64

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.64

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64

Divergent evolution of dispersal in a heterogeneous landscape. Evolution (2001) 1.63

Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (2008) 1.61

Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis (2008) 1.60

Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis (2004) 1.58

Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania. Ann Rheum Dis (2003) 1.58

Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry. Ann Rheum Dis (2009) 1.56

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis (2003) 1.55

Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. Rheumatology (Oxford) (2003) 1.55

Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis (2005) 1.54

Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int (2001) 1.53

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53

Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol (1994) 1.52

Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51

Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis (2007) 1.51

Comparative allozyme and microsatellite population structure in a narrow endemic plant species, Centaurea corymbosa Pourret (Asteraceae). Mol Ecol (2001) 1.51

Conventional treatments for ankylosing spondylitis. Ann Rheum Dis (2002) 1.48

Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol (2000) 1.48

A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun (2008) 1.47

A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 1.46

Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum (1997) 1.46

Dactylitis also involving the synovial sheaths in the palm of the hand: two more cases studied by magnetic resonance imaging. Ann Rheum Dis (1998) 1.44

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis (1999) 1.44